Vaxcyte Launches $1B Dual Offering: Stock, Notes Due 2032

Vaxcyte, Inc. (Nasdaq: PCVX) announced on Oct. 05, 2026 that it has commenced two separate underwritten public offerings: $500 million of common stock and pre-funded warrants, and $500 million aggregate principal amount of convertible senior notes due 2032. The company also intends to grant underwriters a 30-day option for up to an additional $75 million of stock and expects a matching $75 million option on the notes for over-allotments. Both offerings are registered under the Securities Act of 1933 and neither closing is contingent on the other.

Context — Why Does Vaxcyte Need $1 Billion Now?

The company tied the raise directly to its lead vaccine program. Vaxcyte said it intends to use the combined net proceeds to fund clinical development of the VAX-31 adult and pediatric programs, including the ongoing adult Phase 3 studies and the infant Phase 2 dose-finding study.

The report names specific trials. OPUS-2 evaluates concomitant administration with a seasonal influenza vaccine and is described as enrolled. OPUS-3 tests VAX-31 in adults who have previously received a pneumococcal vaccine and is also enrolled. A planned manufacturing consistency study sits alongside both.

Beyond clinical work, proceeds are earmarked for manufacturing scale-up and supply. Vaxcyte said it wants to establish additional manufacturing capacity to meet potential incremental demand from global adult and pediatric populations, and to build inventory ahead of a potential U.S. launch of VAX-31 in adults.

That is a capital-intensive sequence: late-stage trials, parallel infant dosing work, new capacity and pre-launch inventory all running at once. The company did not disclose a cash balance, burn rate or runway figure in the report, so the gap the raise fills cannot be sized from the disclosure alone.

The report gives no prior-period comparable. There is no earlier offering size, no stated shelf capacity remaining and no historical pricing reference. What it does confirm is that the shelf registration statement behind both deals was filed with the SEC and automatically effective on May 24, 2024.

Data — What the Numbers Show

Item	Amount
Common stock and pre-funded warrants	$500 million
Convertible senior notes due 2032	$500 million principal
Underwriter stock option	up to $75 million
Underwriter note option	up to $75 million
Maximum combined gross	$1.15 billion
Note maturity	October 15, 2032
First optional redemption date	October 22, 2029

The notes are senior, unsecured obligations. Interest accrues and is payable semi-annually in arrears. Vaxcyte will settle conversions by paying cash, delivering shares, or a combination, at its election.

Redemption terms carry two triggers. The notes are callable in whole or in part on or after Oct. 22, 2029, but only if the last reported sale price of Vaxcyte common stock exceeds 130% of the conversion price for a specified period. A second trigger allows full redemption if outstanding principal falls below 10% of the aggregate issued.

A fundamental change clause lets noteholders require repurchase for cash at principal plus accrued interest, subject to a limited exception.

The interest rate, initial conversion rate and remaining note terms will be set at pricing. The company did not disclose those figures, nor a pricing date, nor the number of shares offered.

Analysis — What the Structure Signals to Biotech Investors

The split structure matters. Issuing equity and convertibles in parallel lets Vaxcyte raise roughly equal amounts from two different buyer bases, and the report explicitly states neither deal depends on the other closing.

A convertible note due 2032 pushes dilution risk further out than straight equity. Conversion only becomes dilutive if the stock trades well above the conversion price, which is set at pricing. The 130% redemption threshold means Vaxcyte can force conversion once the shares clear a premium to that level.

Equity holders absorb immediate dilution from the $500 million stock tranche. Noteholders take credit and conversion risk instead. The two groups are exposed to the same clinical catalysts but through different payoff structures.

One limitation stands out. No pricing terms are disclosed, so the cost of capital is unknown. A biotech with a late-stage asset can price convertibles cheaply; the report gives no coupon, no conversion premium and no indication of demand. Investors cannot judge whether the raise is accretive to existing holders without those inputs.

On positioning, the underwriter syndicate is unusually deep. Jefferies, Leerink Partners, BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC and Guggenheim Securities are joint book-running managers for the stock offering, with Mizuho as bookrunner and BTIG as lead manager. The note offering uses Jefferies, Leerink, BofA, Goldman and Evercore as joint book-runners, with Guggenheim and Mizuho as bookrunners and Needham & Company as lead manager. J. Wood Capital Advisors is financial advisor on the notes.

A syndicate that broad typically precedes institutional demand that is already sounded out. The report does not say whether the deals are oversubscribed.

Outlook — What to Watch Next

The immediate catalyst is pricing. The report gives no date, so the first signal will be the announced interest rate and conversion rate on the notes, and the share price on the equity tranche.

Second, watch the over-allotment options. Vaxcyte intends to grant a 30-day stock option and expects to grant a 30-day note option, each up to $75 million. If exercised in full, the raise grows from $1 billion to $1.15 billion.

Third, the trial readouts the proceeds fund. Vaxcyte said it anticipates topline safety, tolerability and immunogenicity data from OPUS-2, OPUS-3 and the manufacturing consistency study, plus topline data from the infant Phase 2 primary three-dose series and booster dose. No dates are given for those announcements.

Investors holding PCVX through the pricing window face the standard offering dynamic: new supply into the market, with the final terms determining how much dilution lands and when. The report offers no price level, no support zone and no moving average to anchor against.

Frequently Asked Questions

What does a pre-funded warrant mean for Vaxcyte investors?

A pre-funded warrant lets a buyer pay nearly the full share price upfront while deferring the actual share issuance. It functions like common stock economically but shifts the delivery date. Vaxcyte included pre-funded warrants alongside the $500 million stock tranche, which lets certain investors who face ownership limits participate without immediately breaching those thresholds. The report does not specify the warrant exercise price or the split between shares and warrants.

How do the convertible notes due 2032 protect Vaxcyte's balance sheet?

The notes mature Oct. 15, 2032, giving Vaxcyte roughly six years before principal repayment. Interest is payable semi-annually in arrears, and Vaxcyte can settle conversions in cash, stock or a mix at its election. That flexibility lets it manage dilution depending on where the share price sits. The notes are senior and unsecured, ranking above equity but without collateral backing.

Why did Vaxcyte split the raise into two separate offerings?

The report states neither offering's completion is contingent on the other. That means Vaxcyte could close the equity tranche without the notes, or the reverse. Running both simultaneously reaches two distinct investor pools — equity buyers and convertible arbitrage funds — and the combined $1 billion target, or $1.15 billion with over-allotments, is larger than either alone. The company did not explain the strategic rationale.

Bottom Line

Vaxcyte is raising up to $1.15 billion across equity and 2032 convertibles, with pricing terms still undisclosed.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.